Tissue Regenix Group PLC Change of Registered Office (5398D)
October 29 2020 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 5398D
Tissue Regenix Group PLC
29 October 2020
Tissue Regenix Group plc
Change of registered office
Leeds, 29 October 2020 - Tissue Regenix Group (AIM:TRX) the
regenerative medical devices company announces that the Company's
registered office and UK manufacturing facility has changed with
immediate effect from Unit 1 & 2, Astley Way, Astley Lane
Industrial Estate, Swillington, LS26 8XT to: Unit 3, Phoenix Court,
Lotherton Way, Garforth, LS25 2GY.
The decision to undertake this move was initially announced in
August, as part of ongoing overhead cost reduction initiatives, and
it is expected to deliver savings of over GBP0.4m on an annualised
basis from 2021.
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3073
Caitlin Pearson Head of Communications
------------------------------------------ --------------------
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710 7600
Adviser and Broker)
Ben Maddison/Alex Price
------------------------------------------ --------------------
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopaedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CROZZMZGRRDGGZM
(END) Dow Jones Newswires
October 29, 2020 03:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2023 to Apr 2024